Development and release mechanism of diltiazem HCl prolonged release matrix tablets.
A coated matrix tablet formulation has been used to develop controlled release diltiazem HCl (DIL) tablets. The developed drug delivery system provided prolonged drug release rates over a defined period of time. DIL tablets prepared using dry mixing and direct compression and the core consisted of hydrophilic and hydrophobic polymers such as hydroxypropylmethylcellulose (HPMC), Eudragits RLPO/RSPO, microcrystalline cellulose, and lactose. Tablets were coated with Eudragit NE 30D, and the influence of varying the inert hydrophobic polymers and the amount of the coating polymer were investigated. The release profile of the developed formulation was described by the Higuchi model. Stability trials up to 6 months displayed excellent reproducibility.
Boyapally
Harikrishna
H
Pharmaceutical Sciences, Greenwich University, Medway Campus, Chatham Maritime, Kent, UK.
Nukala
Ravi Kumar
RK
Douroumis
Dionysios
D
D000180:Acrylic Resins / Q000737:chemistry; D001682:Biological Availability; D002482:Cellulose / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000737:chemistry*; D004110:Diltiazem / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004355:Drug Stability; D057927:Hydrophobic and Hydrophilic Interactions; D065347:Hypromellose Derivatives; D007700:Kinetics; D007785:Lactose / Q000737:chemistry; D008689:Methacrylates / Q000737:chemistry; D008747:Methylcellulose / Q000031:analogs & derivatives / Q000737:chemistry; D008855:Microscopy, Electron, Scanning; D008956:Models, Chemical; D011108:Polymers / Q000737:chemistry; D013607:Tablets
D000180:Acrylic Resins; D003692:Delayed-Action Preparations; C477853:Eudragit NE 30-D; D008689:Methacrylates; D011108:Polymers; D013607:Tablets; C050528:Eudragit RS; D065347:Hypromellose Derivatives; C058665:Eudragit RL; D002482:Cellulose; D008747:Methylcellulose; D004110:Diltiazem; D007785:Lactose; C109691:microcrystalline cellulose